Department of Pulmonology, Medical University of Graz and Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Ann Am Thorac Soc. 2024 Aug;21(8):1115-1123. doi: 10.1513/AnnalsATS.202312-1079FR.
The definition of pulmonary hypertension (PH) has been revised recently, with the mean pulmonary artery pressure (mPAP) threshold (assessed by right heart catheterization) reduced from ⩾25 mm Hg to >20 mm Hg. This change reflects the mPAP upper limit of normal and a lower limit that is independently associated with adverse outcomes. To improve the specificity of diagnosing pathogenic increases in mPAP, however, a diagnosis of precapillary PH now also includes pulmonary vascular resistance >2.0 Wood units (WU) (lowered from >3.0 WU). These changes are positioned to capture approximately 55% more patients with PH. Because all clinical trials showing a benefit of pulmonary vasodilator therapy in precapillary PH used the classical hemodynamic definition, the approach to the diagnosis and management of patients with mild PH (i.e., mPAP 21-24 mm Hg and pulmonary vascular resistance 2-3 WU) requires particular consideration. Here, we use a question/answer format to discuss key areas in the management of mild PH, including practical information tailored to clinicians without training in PH.
肺动脉高压(PH)的定义最近已经修订,平均肺动脉压(mPAP)的阈值(通过右心导管检查评估)从 ⩾25mmHg 降低到 >20mmHg。这一变化反映了 mPAP 的正常上限和与不良结局独立相关的下限。然而,为了提高诊断 mPAP 致病升高的特异性,现在也将肺血管阻力 >2.0 伍德单位(WU)(从 >3.0 WU 降低)的前毛细血管 PH 诊断包括在内。这些变化旨在捕获大约 55%的 PH 患者。由于所有显示肺血管扩张剂治疗在前毛细血管 PH 中有益的临床试验都使用了经典的血流动力学定义,因此需要特别考虑轻度 PH(即 mPAP 21-24mmHg 和肺血管阻力 2-3WU)患者的诊断和管理方法。在这里,我们使用问答形式讨论轻度 PH 管理中的关键领域,包括针对没有 PH 培训的临床医生的实用信息。